Enveric Biosciences Stock Performance
| ENVB Stock | USD 2.91 0.16 5.21% |
The firm shows a Beta (market volatility) of 2.1, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Enveric Biosciences will likely underperform. At this point, Enveric Biosciences has a negative expected return of -0.57%. Please make sure to confirm Enveric Biosciences' kurtosis, as well as the relationship between the day median price and period momentum indicator , to decide if Enveric Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Enveric Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (5.21) | Five Day Return (27.97) | Year To Date Return (20.71) | Ten Year Return (100.00) | All Time Return (100.00) |
Last Split Factor 1:12 | Dividend Date 2019-11-25 | Ex Dividend Date 2008-04-23 | Last Split Date 2025-10-28 |
1 | Enveric Biosciences Inc. stock prediction for this week - Market Rally Free Risk Controlled Daily Trade Plans - newser.com | 11/05/2025 |
2 | Will Enveric Biosciences Inc. stock outperform global peers - July 2025 Levels Safe Capital Investment Plans - newser.com | 11/20/2025 |
3 | What analysts say about Enveric Biosciences Inc stock - Dividend Stability Analysis Low Cost Portfolio Growth - earlytimes.in | 12/05/2025 |
4 | Enveric Biosciences Announces Exercise of Warrants for 3.1 Million Gross Proceeds | 12/11/2025 |
5 | How institutional buying supports Enveric Biosciences Inc. stock - 2025 EndofYear Setup Real-Time Volume Spike Alerts - DonanmHaber | 12/19/2025 |
6 | Acquisition by Coveney Kevin Michael of 40198 shares of Enveric Biosciences subject to Rule 16b-3 | 12/23/2025 |
7 | Enveric Biosciences Announces Patent Issuance | 12/29/2025 |
8 | Insider Sell Will Enveric Biosciences Inc SLZ stock see insider accumulation - 2025 Earnings Impact Long-Term Investment Growth Plans - moha.gov.vn | 01/02/2026 |
9 | Why Enveric Biosciences Inc. stock remains resilient - Weekly Investment Summary Target Return Focused Picks - ulpravda.ru | 01/08/2026 |
10 | Enveric Biosciences, Inc. Short Interest Down 45.0 percent in December | 01/15/2026 |
11 | Enveric Biosciences Announces Closing of 1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | 01/28/2026 |
Enveric Biosciences Relative Risk vs. Return Landscape
If you would invest 708.00 in Enveric Biosciences on November 3, 2025 and sell it today you would lose (417.00) from holding Enveric Biosciences or give up 58.9% of portfolio value over 90 days. Enveric Biosciences is currently does not generate positive expected returns and assumes 13.6113% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Enveric, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Enveric Biosciences Target Price Odds to finish over Current Price
The tendency of Enveric Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.91 | 90 days | 2.91 | roughly 97.0 |
Based on a normal probability distribution, the odds of Enveric Biosciences to move above the current price in 90 days from now is roughly 97.0 (This Enveric Biosciences probability density function shows the probability of Enveric Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.1 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Enveric Biosciences will likely underperform. Additionally Enveric Biosciences has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Enveric Biosciences Price Density |
| Price |
Predictive Modules for Enveric Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Enveric Biosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Enveric Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Enveric Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Enveric Biosciences is not an exception. The market had few large corrections towards the Enveric Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Enveric Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Enveric Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.63 | |
β | Beta against Dow Jones | 2.10 | |
σ | Overall volatility | 1.25 | |
Ir | Information ratio | -0.04 |
Enveric Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Enveric Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Enveric Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Enveric Biosciences generated a negative expected return over the last 90 days | |
| Enveric Biosciences has high historical volatility and very poor performance | |
| Enveric Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (9.57 M) with profit before overhead, payroll, taxes, and interest of 8.15 M. | |
| Enveric Biosciences currently holds about 18.01 M in cash with (7.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.44, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Enveric Biosciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Enveric Biosciences Announces Closing of 1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules |
Enveric Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Enveric Stock often depends not only on the future outlook of the current and potential Enveric Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Enveric Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 41.9 K | |
| Cash And Short Term Investments | 2.2 M |
Enveric Biosciences Fundamentals Growth
Enveric Stock prices reflect investors' perceptions of the future prospects and financial health of Enveric Biosciences, and Enveric Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Enveric Stock performance.
| Return On Equity | -2.62 | ||||
| Return On Asset | -1.3 | ||||
| Current Valuation | 510.73 K | ||||
| Shares Outstanding | 518.3 K | ||||
| Price To Book | 1.17 X | ||||
| Price To Sales | 0.08 X | ||||
| Gross Profit | 8.15 M | ||||
| EBITDA | (9.23 M) | ||||
| Net Income | (9.57 M) | ||||
| Cash And Equivalents | 18.01 M | ||||
| Cash Per Share | 11.44 X | ||||
| Total Debt | 1.49 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.33 X | ||||
| Book Value Per Share | 8.66 X | ||||
| Cash Flow From Operations | (7.73 M) | ||||
| Earnings Per Share | (119.64) X | ||||
| Market Capitalization | 2.83 M | ||||
| Total Asset | 3.08 M | ||||
| Retained Earnings | (106.07 M) | ||||
| Working Capital | 1.24 M | ||||
About Enveric Biosciences Performance
By analyzing Enveric Biosciences' fundamental ratios, stakeholders can gain valuable insights into Enveric Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Enveric Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Enveric Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (86.74) | (82.40) | |
| Return On Tangible Assets | (3.62) | (3.80) | |
| Return On Capital Employed | (6.95) | (6.61) | |
| Return On Assets | (3.57) | (3.75) | |
| Return On Equity | (6.91) | (6.57) |
Things to note about Enveric Biosciences performance evaluation
Checking the ongoing alerts about Enveric Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Enveric Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Enveric Biosciences generated a negative expected return over the last 90 days | |
| Enveric Biosciences has high historical volatility and very poor performance | |
| Enveric Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (9.57 M) with profit before overhead, payroll, taxes, and interest of 8.15 M. | |
| Enveric Biosciences currently holds about 18.01 M in cash with (7.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.44, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Enveric Biosciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Enveric Biosciences Announces Closing of 1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules |
- Analyzing Enveric Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Enveric Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Enveric Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Enveric Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Enveric Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Enveric Biosciences' stock. These opinions can provide insight into Enveric Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Enveric Stock analysis
When running Enveric Biosciences' price analysis, check to measure Enveric Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enveric Biosciences is operating at the current time. Most of Enveric Biosciences' value examination focuses on studying past and present price action to predict the probability of Enveric Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enveric Biosciences' price. Additionally, you may evaluate how the addition of Enveric Biosciences to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |